Shares of Alvotech (NASDAQ:ALVO – Get Free Report) fell 7.6% on Friday. The company traded as low as $4.36 and last traded at $4.3150. 108,178 shares were traded during trading, a decline of 86% from the average session volume of 773,409 shares. The stock had previously closed at $4.67.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on ALVO shares. Wall Street Zen cut shares of Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Jefferies Financial Group began coverage on shares of Alvotech in a research note on Tuesday. They set a “buy” rating and a $9.00 price target on the stock. Zacks Research lowered Alvotech from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. UBS Group set a $8.00 price objective on shares of Alvotech in a research note on Wednesday, September 16th. Finally, Barclays upgraded shares of Alvotech from an “underweight” rating to an “overweight” rating and raised their price target for the company from $4.00 to $8.00 in a report on Wednesday, September 16th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Alvotech presently has a consensus rating of “Hold” and a consensus target price of $8.40.
View Our Latest Research Report on ALVO
Alvotech Trading Down 10.0%
The company has a market cap of $1.27 billion, a P/E ratio of -5.13 and a beta of 0.24. The company’s 50-day moving average price is $5.26 and its two-hundred day moving average price is $4.21.
Alvotech (NASDAQ:ALVO – Get Free Report) last released its earnings results on Wednesday, November 11th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $111.60 million for the quarter, compared to the consensus estimate of $125.20 million. As a group, analysts anticipate that Alvotech will post -0.01 earnings per share for the current year.
Hedge Funds Weigh In On Alvotech
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Alvotech during the 2nd quarter valued at approximately $6,376,000. China Universal Asset Management Co. Ltd. increased its position in Alvotech by 24.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 61,712 shares of the company’s stock worth $365,000 after buying an additional 12,049 shares during the period. Renaissance Technologies LLC lifted its stake in Alvotech by 146.9% in the first quarter. Renaissance Technologies LLC now owns 63,200 shares of the company’s stock valued at $217,000 after buying an additional 37,600 shares during the last quarter. Ulland Investment Advisors LLC lifted its stake in Alvotech by 5.0% in the third quarter. Ulland Investment Advisors LLC now owns 115,000 shares of the company’s stock valued at $667,000 after buying an additional 5,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Alvotech during the third quarter valued at $100,000.
Alvotech Company Profile
Alvotech is a biopharmaceutical company based in Reykjavik, Iceland, focused on developing and manufacturing biosimilars—medicines designed to be highly similar to existing biologic drugs. Its work includes biosimilars for conditions in areas such as immunology and oncology. Founded in 2013 by entrepreneur Robert Wessman, the company operates an integrated development and manufacturing platform in Iceland. Alvotech works with commercial partners to seek regulatory approval for and distribute its products in markets including the United States and Europe.
Featured Stories
- Five stocks we like better than Alvotech
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
